单位：[1]Department of Medicine and Therapeutics, Carol and Richard Yu Peritoneal Dialysis Research Centre, Prince of Wales Hospital,Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China[2]Department of Nephrology, Hospital Kuala Lumpur, KualaLumpur, Malaysia[3]Department of Medicine, Faculty of Medicine, University of Malaysia, Kuala Lumpur, Malaysia[4]Institute ofDigestive Diseases, Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong, SAR, China[5]StateKey Laboratory of Digestive Disease, Chinese University of Hong Kong, Hong Kong SAR, China[6]Division of Gastroenterology &Hepatology, National University Hospital, Singapore[7]Division of Nephrology and Kidney Institute, Department of InternalMedicine, China Medical University and Hospital, Taichung, Taiwan[8]Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China[9]State Key Lab for Liver Research, The University of Hong Kong, Hong Kong, China[10]Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Siriraj Hospital, MahidolUniversity, Bangkoknoi, Bangkok, Thailand[11]Division of Nephrology, Department of Medicine, Yong Loo Lin School of Medicine,National University of Singapore, Singapore[12]Jockey Club School of Public Health and Primary Care, The Chinese University ofHong Kong, Hong Kong, China[13]Tomishiro Central Hospital, Okinawa, Japan[14]Department of Internal Medicine, GangnamSeverance Hospital, Yonsei University College of Medicine, Seoul, Korea[15]Center of Excellence in Kidney Metabolic Disorders,Chulalongkorn University, Bangkok, Thailand[16]Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand[17]Department of Nephrology, First Affiliated Hospital, College of Medicine, Xi’an JiaotongUniversity, Xi’an, China[18]Beijing Friendship Hospital, Capital Medical University, Beijing, China首都医科大学附属北京友谊医院[19]Department of Medical Science, Kawasaki Medical School, Okayama, Japan[20]Department of Nephrology, 2nd Xiangya Hospital, Central South University,Changsha, China[21]Department of Medicine and Geriatrics, Kwong Wah Hospital, Hong Kong, China[22]Department of Medicine,Tung Wah Hospital, Hong Kong, China[23]Department of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong, China[24]Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan[25]Kidney Disease: Improving Global Outcomes (KDIGO), Brussels, Belgium[26]Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium
In 2018, Kidney Disease: Improving Global Outcomes (KDIGO) published a clinical practice guideline on the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD). The guideline synthesized recent advances, especially in HCV therapeutics and diagnostics, and provided clinical recommendations and suggestions to aid healthcare providers and improve care for CKD patients with HCV. To gain insight into the extent that the 2018 guideline has been adopted in Asia, KDIGO convened an HCV Implementation Summit in Hong Kong. Participants included nephrologists, hepatologists, and nurse consultants from 8 Southeast Asian countries or regions with comparable high-to-middle economic ranking by the World Bank: mainland China, Hong Kong, Japan, Malaysia, Singapore, South Korea, Taiwan, and Thailand. Through presentations and discussions, meeting participants described regional practice patterns related to the KDIGO HCV in CKD guideline, identified barriers to implementing the guideline, and developed strategies for overcoming the barriers in Asia and around the world.
基金：
KDIGO; Fresenius Medical Care; Merck, Sharp Dohme, Corp.Merck & Company
第一作者单位：[1]Department of Medicine and Therapeutics, Carol and Richard Yu Peritoneal Dialysis Research Centre, Prince of Wales Hospital,Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China[*1]Department of Medicine and Therapeutics, Carol and Richard Yu PD Research Centre, Prince of Wales Hospital, Chinese University of Hong Kong, 30–32 Ngan Shing Street, Shatin, New Territories, Hong Kong, China.
通讯作者：
通讯机构：[1]Department of Medicine and Therapeutics, Carol and Richard Yu Peritoneal Dialysis Research Centre, Prince of Wales Hospital,Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China[26]Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium[*1]Department of Medicine and Therapeutics, Carol and Richard Yu PD Research Centre, Prince of Wales Hospital, Chinese University of Hong Kong, 30–32 Ngan Shing Street, Shatin, New Territories, Hong Kong, China.[*2]Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium.
推荐引用方式(GB/T 7714)：
Philip Kam-Tao Li,Sunita Bavanandan,Rosmawati Mohamed,et al.2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report[J].KIDNEY INTERNATIONAL REPORTS.2020,5(8):1129-1138.doi:10.1016/j.ekir.2020.05.001.
APA：
Philip Kam-Tao Li,Sunita Bavanandan,Rosmawati Mohamed,Cheuk-Chun Szeto,Vincent Wai-Sun Wong...&Michel Jadoul.(2020).2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report.KIDNEY INTERNATIONAL REPORTS,5,(8)
MLA：
Philip Kam-Tao Li,et al."2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report".KIDNEY INTERNATIONAL REPORTS 5..8(2020):1129-1138
医学